Skip to main content
SpringerLink
Log in
Book cover

Renal Anemia pp 15–28Cite as

Has the best route of administration for epoetin been established?

  • Chapter

  • 110 Accesses

Abstract

The best route for administration of erythropoietin in patients with end stage renal disease (ESRD) continues to spark debate. In the USA, the intravenous (IV) route is most widely used, mostly for convenience, despite the demonstration that total weekly dose to achieve/maintain a given target hemoglobin (Hb) level is lower with subcutaneously (SC) administered erythropoietin [1]. The interplay between dose, efficacy, acquisition cost, and revenue generation engages prioritization of both known factors physiology of erythropoiesis, pharmacokinetics of erythropoiesis, desired target hemoglobin, dose size effect, underlying illnesses — and uncertain factors, such as the optimal (best) target hemoglobin and each individual patient’s physiologic response.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Kaufman JS, Reda DJ, Fye CI, Goldfarb DS, Henderson WG, Kleinmann JG, Vaamonde CA. Subcutaneous compared to intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemo-dialysis patients. N Engl J Med .1998;339:578–83.

    Article  PubMed  CAS  Google Scholar 

  2. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30:S192–240.

    Google Scholar 

  3. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, for the End-Stage Renal Disease Core Indicators Work Group. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 end-stage renal disease core indicators project. Am J Kidney Dis. 2001;37(5);E36.

    Article  PubMed  CAS  Google Scholar 

  4. Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, Segner A. European best practice guidelines 9–13 anaemia management. Nephrol Dial Transplantation. 2000;15(supplement 4):33–42.

    Google Scholar 

  5. Albitar S, Meulders O, Hammoud H, Soutif C, Bouvier P, Pollini J. Sub-cutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplantation. 1995;l()(supplement 6):40–3.

    Google Scholar 

  6. Paganini EP, Eschbach JW, Lazarus JM, Van Stone JC, Gimenez LF, Graber SE, Egrie JC, Okamoto DM, Goodkin DA. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am J Kidney Dis. 1995;26(2):331–40.

    Article  PubMed  CAS  Google Scholar 

  7. Tomson CRV, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol Dial Transplantation, 1992;7:129–32.

    CAS  Google Scholar 

  8. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical Pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405–16.

    PubMed  CAS  Google Scholar 

  9. Eidemak I, Friedberg MO, Ladefoged SD, Lokkegaard H, Pedersen E, Skielboe M. Intra-venous versus subcutaneous administration of recombinant human erythropoietin in patients on haemodialysis and CAPD. Nephrol Dial Transplantation 1992;7:526–9.

    CAS  Google Scholar 

  10. Muirhead N, Churchill DN, Goldstein M, Nadler SP, Posen G, Wong C, Slaughter D, Laplante P. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am J Nephrol. 1992;12:303–10.

    Article  PubMed  CAS  Google Scholar 

  11. Barclay PG, Fischer ER, Harris DCH. Interpatient variation in response to subcutaneous versus intravenous low dose erythropoietin. Clin Nephrol. 1993; 40(5):277–80.

    PubMed  CAS  Google Scholar 

  12. Schaller R, Sperschneider H, Thieler H, Dutz W, Hans S, Voigt D, Marx M, Engelmann J, Schoter K-H, Scigalla P, Stein G. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: a multicenter trial. Artif Organ. 1994;18(8):552–8.

    Article  CAS  Google Scholar 

  13. Parker KP, Mitch WE, Stivelman JC, Macon EJ, Bailey JL, Sands JM. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol. 1997;8:288–93.

    PubMed  CAS  Google Scholar 

  14. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. Eur J Clin Pharmacol. 1996;50: 171–7.

    Article  PubMed  CAS  Google Scholar 

  15. Erslev AJ. Erythropoietin. N Engl J Med. 1991;324:1339–44.

    Article  PubMed  CAS  Google Scholar 

  16. Ross R, McCrea JB, Besarab A. Erythropoietin response to blood loss in hemodialysis patients in blunted but preserved. ASAIO J. 1994;40:M880–5.

    Article  PubMed  CAS  Google Scholar 

  17. Fogh J. The increased dose response of ESF after ESF stimulation. Ann NY Acad Sci. 1968;149:217–22.

    Article  PubMed  CAS  Google Scholar 

  18. Gurney CW, Wackman N, Filmanowitz E. Studies on erythropoiesis. XVII. Some quantitative aspects of the erythropoietic response to erythropoietin. Blood. 1961;17:531–46.

    PubMed  CAS  Google Scholar 

  19. Veng-Pendersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, Lowe LS. Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci. 1995;84:760–7.

    Article  Google Scholar 

  20. McMahon FG, Vargas R, Ryan M, Jain AK, Abels RI, Smith PB, Smith IL. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990;76: 1718–22.

    PubMed  CAS  Google Scholar 

  21. Hughes RT, Cotes PM, Oliver DO, et al. Correction of anemia of chronic renal failure with erythropoietin: pharmacokinetic studies in patients on hemodialysis and CAPD. Contrib Nephrol. 1989;76:122–30.

    PubMed  CAS  Google Scholar 

  22. Salmonson T. Pharmacokinetic and pharmacodynamic studies on recombinant human erythropoietin. Scand J Urol Nephrol. 1990;129(supplement):l–66.

    Google Scholar 

  23. Nielsen OJ. Pharmacokinetics of recombinant human erythropoietin in chronic haemodialysis patients. Pharmacol Toxicol. 1990;66:83–6.

    Article  PubMed  CAS  Google Scholar 

  24. Lui SF, Wong KC, Li PKT, Lai KN. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients. Am J Nephrol. 1992;12:55–60.

    Article  PubMed  CAS  Google Scholar 

  25. Besarab A, Nasca T, Ross R. Erythropoietin in patients prior to end-stage renal disease. Curr Opin Nephrol Hypertens. 1995;4:155–61.

    Article  PubMed  CAS  Google Scholar 

  26. Granneloras C, Branger B, Shaldon S, et al. Subcutaneous erythropoietin: a comparison of daily and thrice weekly administration. Contrib Nephrol. 1991;88: 144–51.

    Google Scholar 

  27. Sohmiya M. Kabika T, Kato Y. Therapeutic use of continued subcutaneous infusion of recombinant human erythropoietin in malnourished predialysis anemic patients with diabetic nephropathy. Eur J Endocrinol. 1998;139:367–70.

    Article  PubMed  CAS  Google Scholar 

  28. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamato DM, Schwab SC, Goodkin DA. The effects of normal versus anemic hematocrit on hemodialysis patients with cardiac disease. N Eng J Med. 1998;339:584–90.

    Article  CAS  Google Scholar 

  29. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol. 1999;10:610–19.

    PubMed  CAS  Google Scholar 

  30. Flaherty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther. 1990;47:557–64.

    Article  Google Scholar 

  31. Eschbach JW, Abudulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multi-center clinical trial. Ann Intern Med. 1989;111:992–1000.

    Article  PubMed  CAS  Google Scholar 

  32. Sabota JT. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. Contrib Nephrol. 1989; 76:166–78.

    Google Scholar 

  33. Walter J, Gal J, Taraba I. The beneficial effect of low initial dose and gradual increase of erythropoietin treatment in hemodialysis patients. Artif Organs. 1995;19:76–80.

    Article  PubMed  CAS  Google Scholar 

  34. Eschbach JW. Erythropoietin 1991 — An overview. Am J Kidney Dis. 1991;18 (supplement 4):3–9.

    PubMed  CAS  Google Scholar 

  35. Caro J, Brown S, Miller OP, Murky T, Erslev AJ. Erythropoietin levels in uremic nephric and anephric patients. J Lab Clin Med. 1979;93:449–58.

    PubMed  CAS  Google Scholar 

  36. Zaroulis CHG, Hoffman BJ, Kourides IA. Serum concentration of erythropoietin measured by radioimmunoassay in hematologic disorders and chronic renal failure. Am J Hematol. 1981;11:85–92.

    Article  PubMed  CAS  Google Scholar 

  37. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer H-H. The pharmacokinetics and pharmacodynamics or recombinant human erythropoietin in hemodialysis patients. Br J Clin Pharmacol. 1992;34:449–508.

    Google Scholar 

  38. Grannolleras C, Branger B, Beau MC, Deschodt G, Alsabadani B, Shaldon S. Experience with daily self-administered subcutaneous erythropoietin. Contrib Nephrol. 1989;76:143–8.

    Google Scholar 

  39. Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999;10:2392–5.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. Anatole Besarab
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rebecca Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Besarab, A., Schmidt, R. (2002). Has the best route of administration for epoetin been established?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_3

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_3

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation